At present, ICIs, which are widely used in HNSCC patients, mainly act on PD-1 (PDCD1)/PD-L1 (CD274) and CTLA-4, while targeted therapeutic drugs mainly act on EGFR [69,70]. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.